Granulomatosis with polyangiitis

This study looked at 159 people with granulomatosis with polyangiitis (GPA), a rare disease that causes inflammation of blood vessels. Participants were randomly assigned to either stay on a low 5 mg daily dose of prednisone or slowly stop it over six months. The goal was to see …

This study followed 591 adults with eosinophilic granulomatosis with polyangiitis (EGPA) across Europe to see how well mepolizumab 300mg every 4 weeks works over the long term in everyday medical practice. Researchers looked at disease control, lung function, and safety by review…

This study followed about 300 people with EGPA (a rare disease causing inflammation in blood vessels) who were treated with Nucala injections for up to 2 years. Researchers monitored side effects, how well the drug controlled symptoms, and how long it took for the disease to flar…

This completed study looked at the safety and effectiveness of FASENRA (benralizumab) in 51 Korean adults with severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA). Researchers tracked side effects and how well the drug controlled symptoms during rou…

This early study looked at a new drug, MT-2990, in 5 people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal was to see if the drug is safe and how it affects disease activity. Researchers measured changes in symptoms, imagin…

This study tested whether the drug rituximab can help people with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA) achieve remission better than standard treatments. 107 adults with active EGPA were randomly assigned to receive either rituximab or conven…

This study looked at 201 Canadian patients with ANCA-associated vasculitis to see if cheaper biosimilar versions of rituximab work as well as the original drug. Researchers compared disease control, side effects, and how long it took to get insurance approval for treatment. The g…

This study tested whether rosuvastatin, a common cholesterol-lowering drug, could reduce early signs of artery hardening in 121 people with ANCA-associated vasculitis. Participants were in remission and received either rosuvastatin or a placebo for up to 2 years. The goal was to …

This study tested whether giving a stronger pneumococcal vaccine schedule (either two doses close together or a single larger dose) followed by a standard booster could improve immune protection in 96 adults with ANCA-associated vasculitis who are also receiving rituximab therapy…

This study tested whether rituximab (given as an infusion every 6 months) is better than azathioprine (daily pills) at keeping eosinophilic granulomatosis with polyangiitis (EGPA) in remission. 98 adults with newly diagnosed or relapsing EGPA who had already achieved remission to…

This study tested whether rituximab, a targeted antibody therapy, is better than azathioprine, a standard immune-suppressing drug, at preventing relapses in people with ANCA-associated vasculitis. 117 patients who had achieved remission were randomly assigned to receive either ri…

This study looked at whether giving rituximab for 46 months instead of the usual 18 months can better prevent relapses of ANCA-associated vasculitis, a rare autoimmune disease that causes blood vessel inflammation. 97 patients who were already in remission after initial rituximab…

This study tested whether adding azathioprine to standard corticosteroid treatment helps people with certain types of vasculitis (blood vessel inflammation) achieve remission and avoid relapses. 114 newly diagnosed patients without poor prognosis factors took part. The goal was t…

This study tested two ways of giving rituximab to people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. All 166 participants were in remission and received rituximab either on a fixed schedule or only when certain blood markers (ANC…

This study looked at 52 adults with EGPA (a rare inflammatory disease) and severe chronic sinusitis with nasal polyps. They received mepolizumab 300 mg every 4 weeks. The goal was to see if the drug reduces polyp size and improves symptoms like nasal congestion and sense of smell…

This study tested whether a low dose (4.5 mg) of naltrexone, a drug already used for alcoholism, can improve physical health and quality of life in people with vasculitis. Sixty participants took either the drug or a placebo daily for six weeks. The goal was to see if the drug le…

This study looks at whether a protein in the blood, called soluble CD95 ligand, plays a role in ANCA-associated vasculitis, a rare group of diseases that cause inflammation of blood vessels. Researchers will collect blood and urine samples from 48 adults with the condition and tr…

This study explores whether a special type of PET/CT scan, using a radioactive tracer called 18F-FDG, can accurately measure disease activity in people with granulomatosis with polyangiitis (GPA), a rare condition that causes inflammation of blood vessels. Researchers will compar…

This completed study looked at over 107,000 patients in Germany to understand the long-term side effects of systemic steroids (corticosteroids) used for conditions like asthma, COPD, and arthritis. Researchers compared patients who took steroids with those who did not, tracking r…

This study looked at immune cells from 138 people with Wegener's granulomatosis, a rare disease causing inflammation of blood vessels. Researchers measured levels of a protein called DAP12 in different immune cells to understand how the disease works. No new treatment was tested;…

This study compares two blood-filtering techniques—plasma exchange and immunoadsorption—in 40 patients with severe kidney failure caused by ANCA vasculitis or Goodpasture disease. The goal is to see which method removes disease-causing antibodies more quickly. Results may help do…

This study looked at how certain immune cells, called neutrophils, behave in people with granulomatosis with polyangiitis (GPA), a rare blood vessel inflammation disease. Researchers collected blood samples from 93 participants, including patients with GPA and other related condi…